Scholarlink

Background <p>Carfilzomib (Kyprolis™) is a second-generation proteasome inhibitor registered for the management of relapsed or refractory multiple myeloma. Drug safety profile includes hypertension, heart failure, and acute kidney failure. There are only scarce data on carfilzomib pulmonary toxicity.</p> Case description <p>In this report, we present a case of a Caucasian man in his 50s diagnosed with multiple myeloma and treated with daratumumab–carfilzomib–dexamethasone as second-line therapy. After 5&#xa0;months of treatment, the patient developed noninfectious interstitial pneumonitis with respiratory failure. After a thorough differential diagnosis, we identified the patient’s symptoms as a direct result of drug administration. Carfilzomib withdrawal alone led to clinical and radiologic improvement, whereas reintroducing the therapy worsened the condition. Daratumumab as monotherapy was continued without adverse events. The precise cause of carfilzomib pulmonary toxicity remains unknown.</p> Conclusion <p>Given the rarity of the reported syndrome, our case highlights the need to monitor pulmonary function on carfilzomib treatment, as well as the possibility of symptom cessation on early drug withdrawal without additional interventions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pulmonary toxicity induced by carfilzomib: a case report and review of the literature

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Mateusz Ziarkiewicz,
  • Aleksandra Zacny,
  • Grzegorz Basak,
  • Laretta Grabowska-Derlatka

摘要

Background

Carfilzomib (Kyprolis™) is a second-generation proteasome inhibitor registered for the management of relapsed or refractory multiple myeloma. Drug safety profile includes hypertension, heart failure, and acute kidney failure. There are only scarce data on carfilzomib pulmonary toxicity.

Case description

In this report, we present a case of a Caucasian man in his 50s diagnosed with multiple myeloma and treated with daratumumab–carfilzomib–dexamethasone as second-line therapy. After 5 months of treatment, the patient developed noninfectious interstitial pneumonitis with respiratory failure. After a thorough differential diagnosis, we identified the patient’s symptoms as a direct result of drug administration. Carfilzomib withdrawal alone led to clinical and radiologic improvement, whereas reintroducing the therapy worsened the condition. Daratumumab as monotherapy was continued without adverse events. The precise cause of carfilzomib pulmonary toxicity remains unknown.

Conclusion

Given the rarity of the reported syndrome, our case highlights the need to monitor pulmonary function on carfilzomib treatment, as well as the possibility of symptom cessation on early drug withdrawal without additional interventions.